Ma, L. W. et al. The cost of postoperative pancreatic fistula versus the cost of pasireotide: results from a prospective randomized trial. Ann. Surg. 265, 11–16 (2017).
Williamsson, C., Ansari, D., Andersson, R. & Tingstedt, B. Postoperative pancreatic fistula-impact on outcome, hospital cost and effects of centralization. HPB (Oxford) 19, 436–442 (2017).
Wellner, U. F. et al. A simple scoring system based on clinical factors related to pancreatic texture predicts postoperative pancreatic fistula preoperatively. HPB (Oxford) 12, 696–702 (2010).
Yamamoto, Y. et al. A preoperative predictive scoring system for postoperative pancreatic fistula after pancreaticoduodenectomy. World J. Surg. 35, 2747–2755 (2011).
Roberts, K. J. et al. Scoring system to predict pancreatic fistula after pancreaticoduodenectomy: a UK multicenter study. Ann. Surg. 261, 1191–1197 (2015).
Nishida, Y. et al. Preoperative sarcopenia strongly influences the risk of postoperative pancreatic fistula formation after pancreaticoduodenectomy. J. Gastrointest. Surg. 20, 1586–1594 (2016).
Schuh, F. et al. A Simple Classification of Pancreatic Duct Size and Texture Predicts postoperative Pancreatic Fistula: a classification of the International Study Group of Pancreatic Surgery (ISGPS). Ann. Surg. 277, e597–e608 (2023).
Callery, M. P., Pratt, W. B., Kent, T. S., Chaikof, E. L. & Vollmer, C. M. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J. Am. Coll. Surg. 216, 1–14 (2013).
Nimptsch, U., Krautz, C., Weber, G. F., Mansky, T. & Grützmann, R. Nationwide in-hospital mortality following pancreatic surgery in Germany is higher than anticipated. Ann. Surg. 264, 1082–1090 (2016).
Farges, O. et al. The theory and practice of pancreatic surgery in France. Ann. Surg. 266, 797–804 (2017).
El Amrani, M. et al. Referring patients to expert centers after pancreatectomy is too late to improve outcome. Inter-hospital transfer analysis in nationwide study of 19,938 patients. Ann. Surg. 272, 723–730 (2020).
Mungroop, T. H. et al. Updated alternative fistula risk score (ua-FRS) to include minimally invasive pancreatoduodenectomy: pan-European validation. Ann. Surg. 273, 334–340 (2021).
Casciani, F., Bassi, C. & Vollmer, C. M. Decision points in pancreatoduodenectomy: insights from the contemporary experts on prevention, mitigation, and management of postoperative pancreatic fistula. Surgery 170, 889–909 (2021).
Fong, Z. V. et al. Early drain removal—the middle ground between the Drain versus No Drain debate in patients undergoing pancreaticoduodenectomy: a prospective validation study. Ann. Surg. 262, 378–383 (2015).
Van Hilst, J. et al. The inflammatory response after laparoscopic and open pancreatoduodenectomy and the association with complications in a multicenter randomized controlled trial. HPB 21, 1453–1461 (2019).
Garnier, J. et al. Establishment and external validation of neutrophil-to-lymphocyte ratio in excluding postoperative pancreatic fistula after pancreatoduodenectomy. BJS Open 7, zrac124 (2023).
Søreide, K., Healey, A. J., Mole, D. J. & Parks, R. W. Pre-, peri- and post-operative factors for the development of pancreatic fistula after pancreatic surgery. HPB 21, 1621–1631 (2019).
Verdonk, F. et al. Measuring the human immune response to surgery: multiomics for the prediction of postoperative outcomes. Curr. Opin. Crit. Care 27, 717–725 (2021).
Rumer, K. K. et al. Integrated single-cell and plasma proteomic modeling to predict surgical site complications: a prospective cohort study. Ann. Surg. 275, 582–590 (2022).
Fragiadakis, G. K. et al. Patient-specific immune states before surgery are strong correlates of surgical recovery. Anesthesiology 123, 1241–1255 (2015).
Verdonk, F. et al. An immune signature of postoperative cognitive decline: a prospective cohort study.Int. J. Surg. 110, 7749–7762 (2024).
Garnier, J. et al. Immediate variations in high-dimensional circulating immune cells following pancreatectomy. Clin. Transl. Immunol. 14, e70059 (2025).
Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. M. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med. 13, 1 https://doi.org/10.1186/s12916-014-0241-z (2015).
Bassi, C. et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 161, 584–591 (2017).
Halloran, C. M. et al. A multicenter, randomized, double-blinded, clinical trial comparing Cattell-Warren and Blumgart anastomoses following partial pancreatoduodenectomy: PANasta trial. Ann. Surg. Open 3, e198 (2022).
Turrini, O. & Delpero, J. R. Omental flap for vessel coverage during pancreaticoduodenectomy. A Modified Technique. J. Chir. (Paris) 146, 545–548 (2009).
Pessaux, P. et al. External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy: prospective multicenter randomized trial. Ann. Surg. 253, 879–885 (2011).
Ecker, B. L. et al. Characterization and optimal management of high-risk pancreatic anastomoses during pancreatoduodenectomy. Ann. Surg. 267, 608–616 (2018).
Van Unen, V. et al. Visual analysis of mass cytometry data by hierarchical stochastic neighbour embedding reveals rare cell types. Nat. Commun. 8, 1740 (2017).
Hédou, J. et al. Discovery of sparse, reliable omic biomarkers with Stabl. Nat. Biotechnol. 42, 1581–1593 (2024).
Ahmed, R. et al. CD57+ Memory T cells proliferate in vivo. Cell Rep 33, 108501 (2020).
Björkström, N. K. et al. Elevated numbers of FcγRIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection. J. Immunol. 181, 4219–4228 (2008).
Freuchet, A. et al. Identification of human exTreg cells as CD16+CD56+ cytotoxic CD4+ T cells. Nat. Immunol. 24, 1748–1761 (2023).
Hirono, S. et al. Risk factors for pancreatic fistula grade C after pancreatoduodenectomy: a large prospective, multicenter Japan-Taiwan collaboration study. J. Hepatobiliary Pancreat Sci. 27, 622–631 (2020).
Bassi, C. et al. Pancreatoduodenectomy at the Verona Pancreas Institute: the evolution of indications, surgical techniques, and outcomes: a retrospective analysis of 3000 consecutive cases. Ann. Surg. 276, 1029–1038 (2022).
McMillan, M. T. et al. The characterization and prediction of ISGPF Grade C fistulas following pancreatoduodenectomy. J. Gastrointest. Surg. 20, 262–276 (2016).
Hank, T. et al. Association between pancreatic fistula and long-term survival in the era of neoadjuvant chemotherapy. JAMA Surg. 154, 943 (2019).
Reinke, S. et al. Terminally differentiated CD8+ T cells negatively affect bone regeneration in humans. Sci. Transl. Med. 5, 177ra36 (2013).
Slade, M., Simmons, R., Yunis, E. & Greenberg, L. Immunodepression after major surgery in normal patients. Surgery 8, 363–372 (1975).
Cohen, J. T., Charpentier, K. P., Miner, T. J., Cioffi, W. G. & Beard, R. E. Lymphopenia following pancreaticoduodenectomy is associated with pancreatic fistula formation. Ann. Hepatobiliary Pancreat Surg. 25, 242–250 (2021).
Chretien, A. S. et al. Natural killer defective maturation is associated with adverse clinical outcome in patients with acute myeloid leukemia. Front. Immunol. 8, 573 (2017).
Conway Morris, A. et al. Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Med. 44, 627–635 (2018).
Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).
Werba, G. et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat. Commun. 14, 797 (2023).
Middelburg, J. et al. The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. Cell Rep. 42, 113516 (2023).
Hyung, J. et al. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX. ESMO Open 7, 100484 (2022).
Shinde, R. S. et al. External validation and comparison of the original, alternative and updated-alternative fistula risk scores for the prediction of postoperative pancreatic fistula after pancreatoduodenectomy. Pancreatology 20, 751–756 (2020).
Gu, Z. et al. Development and validation of a novel nomogram to predict postoperative pancreatic fistula after pancreatoduodenectomy using lasso-logistic regression: an international multi-institutional observational study. Int. J. Surg. 109, 4027–4040 (2023).
Ashraf Ganjouei, A. et al. A machine learning approach to predict postoperative pancreatic fistula after pancreaticoduodenectomy using only preoperatively known data. Ann. Surg. Oncol. 30, 7738–7747 (2023).
Verma, A. et al. Machine learning-based prediction of postoperative pancreatic fistula following pancreaticoduodenectomy. Ann. Surg. 280, 325–331 (2024).
Ingwersen, E. W. et al. Radiomics preoperative-Fistula risk score (RAD-FRS) for pancreatoduodenectomy: development and external validation. BJS Open 7, zrad100 (2023).
Mišić, V. V., Gabel, E., Hofer, I., Rajaram, K. & Mahajan, A. Machine learning prediction of postoperative emergency department hospital readmission. Anesthesiology 132, 968–980 (2020).
Durand, X. et al. Predicthor: AI-powered predictive risk model for 30-day mortality and 30-day complications in patients undergoing thoracic surgery for lung cancer. Ann. Surg. Open 6, e578 (2025).
Tarvainen, T., Sirén, J., Kokkola, A. & Sallinen, V. Effect of hydrocortisone vs pasireotide on pancreatic surgery complications in patients with high risk of pancreatic fistula: a randomized clinical trial. JAMA Surg 155, 291–298 (2020).
Palen, A., Garnier, J., Delpero, J. R., Turrini, O. & Ewald, J. Protective peritoneal patch for arteries during pancreatoduodenectomy: good value for money. Langenbecks Arch Surg 407, 377–382 (2022).
Smits, F. J. et al. Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial. Lancet 399, 1867–1875 (2022).
De Luca, R. et al. Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment. Eur. J. Surg. Oncol. 49, 542–549 (2023).
Barberan-Garcia, A. et al. Personalised prehabilitation in high-risk patients undergoing elective major abdominal surgery: a randomized blinded controlled trial. Ann. Surg. 267, 50–56 (2018).
Cambriel, A. et al. Immune modulation by personalized vs standard prehabilitation before major surgery: a randomized clinical trial. JAMA Surg. 161, 20–30 (2026).
Balzano, G. et al. Total pancreatectomy with islet autotransplantation as an alternative to high-risk pancreatojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. Ann. Surg. 277, 894–903 (2023).
Stoop, T. F. et al. Systematic review and meta-analysis of the role of total pancreatectomy as an alternative to pancreatoduodenectomy in patients at high risk for postoperative pancreatic Fistula: is it a justifiable indication? Ann Surg. 278, e702–e711 (2023).
Davern, M. et al. PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma. Front. Immunol. 14, 1150754 (2023).
Hotchkiss, R. S. et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559). Crit. Care Med. 47, 632–642 (2019).
Becht, E. et al. Reverse-engineering flow-cytometry gating strategies for phenotypic labelling and high-performance cell sorting. Bioinformatics 35, 301–308 (2019).
De Graaf, N. et al. Minimally invasive versus open pancreatoduodenectomy for resectable neoplasms. NEJM Evid. 4, EVIDoa2500045 (2025).
Maslove, D. M. et al. Redefining critical illness. Nat. Med. 28, 1141–1148 (2022).